Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1386P - Validation of MET amplification using next-generation sequencing in lung adenocarcinoma

Date

21 Oct 2023

Session

Poster session 20

Topics

Laboratory Diagnostics;  Pathology/Molecular Biology;  Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Marta Salido

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

M. Salido1, S. Clavé2, I. Sánchez3, P. Rocha4, L. Masfarre Pinto5, N. Navarro Gorro5, M.A. GALINDO CAMPOS4, R. Del Rey-Vergara4, A. Taus Garcia6, B. Espinet1, E. Arriola5, B. Bellosillo Paricio7

Author affiliations

  • 1 Molecular Cytogenetics Laboratory, Hospital del Mar - Parc de Salut Mar, 08003 - Barcelona/ES
  • 2 Molecular Biology Laboratory, Hospital del Mar - Parc de Salut Mar, 08003 - Barcelona/ES
  • 3 Pathology Department, Hospital del Mar - Parc de Salut Mar, 08003 - Barcelona/ES
  • 4 Cancer Research Program, IMIM - Institut Hospital del Mar d'Investigacions Mediques, 08003 - Barcelona/ES
  • 5 Medical Oncology Department, Hospital del Mar - Parc de Salut Mar, 08003 - Barcelona/ES
  • 6 Medical Oncology Department, Hospital del Mar - Parc de Salut Mar, 8003 - Barcelona/ES
  • 7 Molecular Biology Laboratory, Hospital del Mar - Parc de Salut Mar, 8003 - Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1386P

Background

MET gene amplification is a potential therapeutic target in lung adenocarcinoma (LUAD) currently identified by fluorescence in situ hybridization (FISH). Next-generation sequencing (NGS) has become an essential diagnostic tool for routine biomarker profiling of cancer patients, including the detection of copy number alterations (CNAs). The aim of this study was to evaluate the concordance between these two methods and identify potential limitations of NGS implementation.

Methods

Thirty cases with MET amplification detected by FISH were retrospectively selected from a cohort of 567 LUAD diagnosed between 2018 and 2022 (prevalence: 5.3%). Cases were classified according to the current Camidge-2021 FISH criteria as 5 low-amplified (MET/CEP7 ratio ≥1.8 to ≤2.2), 11 medium-amplified (MET/CEP7 ratio >2.2 to <4) and 14 high-amplified (MET/CEP7 ratio ≥4). Tumor area and tumor cell percentage were annotated to later evaluate complete molecular alterations by NGS using the Oncomine Precision Assay.

Results

Detection of MET amplification was concordant in only 16 out of 30 cases (5 cases were excluded due to insufficient DNA), and no correlation was found between MET copy number determined by FISH and NGS (R2=0.346). Distribution of amplification categories was random: 2 cases showed low-amplification, 7 medium-amplification, and 7 high-amplification. Slight differences were observed between concordant and discordant cases in: MET enumeration (12.4 vs. 9.3 gene copies), MET/CEP7 ratio (4.8 vs. 3.2), tumor area (15 vs. 11mm2), and DNA concentration (12 vs. 7 ng/μl), but none of them were statistically significant. FISH results of the 9 discordant cases were reviewed and high copy number heterogeneity was observed in 7 of them and focal amplifications were observed in 2. In 7 out of 9 discordant cases, co-alterations were detected: 2 KRAS (p.G12C and p.Q61H), 2 BRAF non-V600, 2 MET exon 14 skipping and one EGFR p.L858R.

Conclusions

The detection of MET amplification by NGS did not show satisfactory concordance with the results obtained by FISH, likely due to the high heterogeneity in MET gene copy number enumeration. As a result, complementary determination by FISH is necessary, given the lack of standardized criteria for establishing CNAs positivity by NGS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.